GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage

Contact sales for details.

Up to 25% of GLP-1 users stopped using insulin within 52 weeks of beginning GLP-1 treatment. Among GLP-1 dugs, Mounjaro usage is driving the biggest decline in insulin according to Earnest’s closed-loop pharmacy claims dataset, Phoenix. The dataset is ideal for longitudinal cohorting analysis for studying long-term implications like concomitant therapy persistence and related drug use of new treatments like GLP-1.

Around 76% of GLP-1 insulin users were still taking insulin a year out from starting a GLP-1. That is meaningfully lower than 83% on Ozempic and 88% on Trulicity. This suggests Mounjaro is the most effective GLP-1 at managing diabetes to a point that patients are no longer dependent on insulin.

Data Disclaimer:

Results reflect data as of December 7th, 2023 when they were prepared. Current results may have changed due to panel and methodology updates.